![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Warns CanaRx Over Drug Distribution ‘Scheme’
FDA Warns CanaRx Over Drug Distribution ‘Scheme’
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
The FDA hit Canadian drug distributor CanaRx with a warning letter, citing the company for supplying unapproved versions of FDA-cleared drugs.
The warning letter, based on a long-term review of the company’s practices, took issue with the company’s substitution of FDA-approved drugs with unapproved drugs, which it supplied to the employees of its clients — employers in both the public and private sector.
Specifically, a note on the invoice template the company uses showed that approved drugs were being substituted with potentially unsafe ones. The disclaimer — “depending on your country, our medications may appear to be different in size, shape or color” — showed that the company “designed its business to operate in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs,” the warning letter said.
Upcoming Events
-
21Oct